TY  - GEN
AU  - Ronchi,Cristina L.
AU  - Altieri,Barbara
AU  - Ronchi,Cristina L.
AU  - Altieri,Barbara
TI  - Present and Future of Personalised Medicine for Endocrine Cancers
SN  - books978-3-0365-4329-1
PY  - 2022///
CY  - Basel
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - Medicine
KW  - bicssc
KW  - papillary thyroid cancer
KW  - SUV PET/CT
KW  - BRAF V600E
KW  - immune checkpoint inhibitors (ICIs)
KW  - ipilimumab
KW  - nivolumab
KW  - prolactinoma
KW  - Cushing's disease
KW  - aggressive pituitary tumor
KW  - aggressive PitNET
KW  - aggressive pituitary adenoma
KW  - pituitary carcinoma
KW  - adrenocortical cancer
KW  - adrenal adenomas
KW  - adrenal tumors
KW  - p53
KW  - p27
KW  - ki-67
KW  - reticulin
KW  - mitotane
KW  - adjuvant treatment
KW  - recurrence
KW  - recurrence free survival
KW  - timing
KW  - intratumoral heterogeneity
KW  - thyroid tumor
KW  - BRAF
KW  - RET/PTC rearrangements
KW  - RAS mutation
KW  - adrenal cortex
KW  - carcinoma
KW  - angiogenesis
KW  - gene expression
KW  - osteopontin
KW  - hyaluronan synthase 1
KW  - multikinase inhibitors
KW  - sorafenib
KW  - lenvatinib
KW  - differentiated thyroid cancer
KW  - radioiodine resistance
KW  - predictive marker
KW  - predictors
KW  - response to treatment
KW  - survival
KW  - information needs and preferences
KW  - focus group interview
KW  - personalized medicine
KW  - neuroendocrine tumours
KW  - phaeochromocytoma
KW  - paraganglioma
KW  - molecular clusters
KW  - n/a
N1  - Open Access
N2  - Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to "personalised cancer medicine". Thanks to developments in genetics, several mutations and gene rearrangements have been identified in patients with endocrine cancers (e.g., thyroid and adrenocortical carcinoma). In particular, each patient can be considered as a unique, individual one, with unique genetic information. The aim of this Special Issue is to offer an overview of exciting new research in the area of endocrine tumours may set the stage for an innovative personalised management and precision medicine modalities for individualised care.New affordable individual genomic analyses, as well as the opportunity to test new compounds in primary cells may allow a personalised management of patients with endocrine malignancies. This approach may improve the prediction of clinical outcome and therapeutic effectiveness, as well as help to avoid the use of ineffective drugs. However, further efforts are needed to obtain an adjustment of clinical management in patients with endocrine cancers that would rely solely or in great part on genetic information. This Special Issue includes basic, translational, and clinical papers on personalised medicine in endocrine malignancies (i.e., thyroid and adrenal), especially focusing on diagnostic and prognostic biomarkers, as well as novel drug targets or targeted treatments, including eventual clinical trials
UR  - https://mdpi.com/books/pdfview/book/5497
UR  - https://directory.doabooks.org/handle/20.500.12854/84513
ER  -